[Epithelial tumours of the thymus]

Area of Science:

• Oncology
• Thoracic Surgery
• Pathology

Context:

• Epithelial thymus tumors (thymomas, thymic carcinomas, neuroendocrine tumors) comprise 20% of mediastinal tumors and 50% of anterior mediastinal tumors.
• Thymomas are frequently linked to autoimmune disorders, most notably myasthenia gravis.
• These tumors exhibit variable clinical behavior, ranging from indolent to metastatic.

Purpose:

• To outline the clinical presentation, staging, classification, and treatment strategies for epithelial thymus tumors.
• To emphasize the importance of the Masaoka staging system and WHO histological classification in guiding management.
• To detail therapeutic approaches for both primary and recurrent thymic malignancies.

Summary:

• Complete surgical resection is the cornerstone of treatment for thymomas and thymic carcinomas.
• Postoperative radiotherapy is indicated for invasive tumors or those with aggressive histology.
• Chemotherapy, typically platinum and anthracycline-based, is used for unresectable or metastatic disease, potentially followed by surgery or radiotherapy.

Impact:

• Improved understanding of thymic malignancies aids in tailoring treatment protocols.
• Accurate staging and classification enhance prognostic predictions for patients.
• Multimodal treatment strategies, including surgery, radiotherapy, and chemotherapy, can improve outcomes for patients with advanced disease.